Clinical Trial Update: Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the combination of docetaxel and thalidomide as second-line therapy for stage III or IV non-small cell lung cancer; the study has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Taxotere (docetaxel)
• Thalomid (thalidomide)

Snippet

Sponsor: University of Virginia | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED